Research programme: Janus kinase inhibitors - YM Biosciences Australia

Drug Profile

Research programme: Janus kinase inhibitors - YM Biosciences Australia

Alternative Names: JAK2 inhibitors - Cytopia

Latest Information Update: 01 Apr 2014

Price : $50

At a glance

  • Originator Cytopia Research; Myomatrix Therapeutics
  • Developer YM BioSciences Australia
  • Class Small molecules
  • Mechanism of Action Janus kinase-2 inhibitors; Vascular endothelial growth factor receptor-1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cancer; Cardiovascular disorders; Pulmonary arterial hypertension

Most Recent Events

  • 01 Apr 2014 Discontinued for Cancer in Australia (unspecified route)
  • 01 Apr 2014 Discontinued for Cardiovascular disorders in USA (unspecified route)
  • 01 Apr 2014 Discontinued for Pulmonary arterial hypertension in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top